No­vo re­ports 're­al­ly pow­er­ful' car­dio, death risk re­duc­tion for semaglu­tide in kid­ney dis­ease

No­vo Nordisk’s semaglu­tide cut the risk of ma­jor car­dio­vas­cu­lar events and death from mul­ti­ple caus­es in a Phase 3 study in­volv­ing pa­tients with type 2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.